Results 191 to 200 of about 113,930 (262)

Subclinical primary aldosteronism. [PDF]

open access: yesArch Endocrinol Metab
Parisien-La Salle S   +4 more
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

open access: yesObesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira   +8 more
wiley   +1 more source

Clinical management of bilateral functional adrenal adenomas. [PDF]

open access: yesJ Surg Case Rep
Melnyk B   +4 more
europepmc   +1 more source

The Renal Micro-Vasculopathy and Systemic Aldosterone-Renin Ratio (ARR) in Type 2 Diabetic Patients-A Retrospective Real-World Study. [PDF]

open access: yesDiabetes Metab Syndr Obes
Wen S   +10 more
europepmc   +1 more source

Evaluating the effect of renin-angiotension-aldosterone system inhibitors and beta blockers on the progression of bicuspid aortic valve aortopathy in adulthood: A retrospective cohort study. [PDF]

open access: yesInt J Cardiol Congenit Heart Dis
Schamroth Pravda N   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy